MCM
SGMT icon

MAI Capital Management’s Sagimet Biosciences SGMT Stock Holding History

MAI Capital Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.61K Hold
500
– – ﹤0.01% 3826
2025
Q4 		$2.96K Hold
500
– – ﹤0.01% 3311
2025
Q3 		$3.43K Sell
500
-261
-34% -$2.12K ﹤0.01% 3150
2025
Q2 		$5.8K Sell
761
-75,591
-99% -$319K ﹤0.01% 2988
2025
Q1 		$249K Buy
76,352
+1,170
+2% +$4.91K ﹤0.01% 1040
2024
Q4 		$338K Buy
75,182
+1,524
+2% +$7.72K ﹤0.01% 959
2024
Q3 		$204K Buy
+73,658
New +$227K ﹤0.01% 1005

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MAI Capital Management's SGMT Position: Q1 2026 in Review

MAI Capital Management held its Sagimet Biosciences (SGMT) position steady in Q1 2026 at 500 shares worth $2.61K. The position accounts for ﹤0.01% of the portfolio, ranked #3826.

MAI Capital Management first reported a position in SGMT in Q3 2024 and has held it in 7 quarters since. The position peaked at $338K in Q4 2024. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • MAI Capital Management held 500 shares of Sagimet Biosciences worth $2.61K as of Q1 2026.
  • MAI Capital Management left its Sagimet Biosciences share count unchanged in Q1 2026.
  • Sagimet Biosciences made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #3826 holding.
  • MAI Capital Management first reported a position in Sagimet Biosciences in Q3 2024 and has held it in 7 quarters since.
  • MAI Capital Management's Sagimet Biosciences position peaked at $338K in Q4 2024.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.